Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Key Points

• Rep. Gilbert Ray Cisneros Jr. sold $15,001–$50,000 of Crinetics Pharmaceuticals shares on July 30, according to a disclosure filed September 4.
• Crinetics shares opened at $84.95, near their 12-month high of $85.01. The company recently beat quarterly EPS and revenue estimates, with revenue up 2,336.9% year over year, though it remains unprofitable.
• Institutional ownership stands at 98.51%, while analysts have an overall “Hold” rating and an average price target of $81.00; several analysts recently downgraded or maintained neutral ratings.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on September 04th, the Representative disclosed that they had sold between $15,001 and $50,000 in Crinetics Pharmaceuticals stock on July 30th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Mesabi Trust NYSE: MSB on 7/31/2026.
• Purchased $1,001 - $15,000 in shares of Praxis Precision Medicines NASDAQ: PRAX on 7/30/2026.
• Purchased $15,001 - $50,000 in shares of Alkermes NASDAQ: ALKS on 7/30/2026.
• Sold $100,001 - $250,000 in shares of Alibaba Group NYSE: BABA on 7/24/2026.
• Sold $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 7/24/2026.
• Sold $1,001 - $15,000 in shares of Viavi Solutions NASDAQ: VIAV on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of SailPoint NASDAQ: SAIL on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of Glacier Bancorp NYSE: GBCI on 7/21/2026.
• Sold $1,001 - $15,000 in shares of FedEx NYSE: FDX on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of Marvell Technology NASDAQ: MRVL on 7/17/2026.

Crinetics Pharmaceuticals Price Performance

Shares of NASDAQ CRNX opened at $84.95 on Tuesday. Crinetics Pharmaceuticals, Inc. has a 12-month low of $30.25 and a 12-month high of $85.01. The company has a market capitalization of $9.01 billion, a PE ratio of -16.86 and a beta of 0.08. The firm's 50-day moving average is $79.85 and its two-hundred day moving average is $52.46.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.18) by $0.04. The firm had revenue of $25.12 million during the quarter, compared to analysts' expectations of $14.84 million. Crinetics Pharmaceuticals had a negative return on equity of 44.22% and a negative net margin of 1,189.88%.The firm's quarterly revenue was up 2336.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.23) EPS. On average, analysts forecast that Crinetics Pharmaceuticals, Inc. will post -4.83 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Stephanie Okey sold 6,900 shares of the firm's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total transaction of $246,123.00. Following the completion of the transaction, the director directly owned 6,400 shares of the company's stock, valued at $228,288. This trade represents a 51.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Vivaldi sold 3,000 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00. Following the completion of the sale, the director owned 19,225 shares in the company, valued at $769,000. This trade represents a 13.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.80% of the company's stock.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Crinetics Pharmaceuticals in the 2nd quarter valued at about $365,179,000. Jupiter Topco LLC bought a new position in shares of Crinetics Pharmaceuticals during the second quarter worth about $170,509,000. California State Teachers Retirement System grew its holdings in shares of Crinetics Pharmaceuticals by 3,523.8% during the second quarter. California State Teachers Retirement System now owns 3,825,409 shares of the company's stock worth $143,147,000 after buying an additional 3,719,846 shares in the last quarter. Wellington Management Group LLP raised its position in Crinetics Pharmaceuticals by 44.3% in the 3rd quarter. Wellington Management Group LLP now owns 8,381,991 shares of the company's stock valued at $349,110,000 after buying an additional 2,574,683 shares during the last quarter. Finally, Baker BROS. Advisors LP raised its position in Crinetics Pharmaceuticals by 488.9% in the 4th quarter. Baker BROS. Advisors LP now owns 1,648,869 shares of the company's stock valued at $76,755,000 after buying an additional 1,368,869 shares during the last quarter. 98.51% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Citizens Jmp cut Crinetics Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. UBS Group restated a "neutral" rating and set a $85.00 price target (up from $55.00) on shares of Crinetics Pharmaceuticals in a research note on Tuesday, July 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen upgraded Crinetics Pharmaceuticals to a "hold" rating in a report on Saturday. Finally, TD Cowen cut Crinetics Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday, July 8th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $81.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.